A recent analysis from UBC Okanagan’s Southern Medical Program (SMP) looked into the usage of personal healthcare technologies and telemedicine to treating Parkinson’s illness sufferers.

Individuals who wish to better both physical and emotional wellbeing were flocking to smart healthcare gadgets. A smart gadget could monitor anything from activity to sleeping habits, calories ingested, and cardiac rhythm.

Wearable Tech And Telehealth For Parkinson’s Disease

However, for clinicians employing online healthcare to manage individuals with severe medical issues quick & reliable information is extremely important.

Wearable Tech And Telehealth For Parkinson's Disease

Dr. Daryl Wile, a motion disease expert and medical assistant professor at SMP, uses telemedicine to contact Parkinson’s sufferers throughout British Columbia’s vast and rocky backcountry.

“Even prior to the pandemic, telehealth helped deliver specialized care to patients living in remote and rural settings,” says Wile, a clinical investigator with the Centre for Chronic Disease Prevention and Management. “But with the complex nature of Parkinson’s, we wanted to enhance these appointments to better understand how movements vary throughout a patient’s entire day.”

These devices are easy to operate and care for. Hence those who suffer from Parkinson’s can also wear them and keep a track of their health condition.

Additionally, these devices can also offer required data to doctors and experts, which can help them decide the line of action for further treatment. In the phase of pandemic technology and such devices have proven highly useful for the patients suffering from various diseases including Parkinson mentioned one of the experts who favor the use of technology.

Wile as well as the study group used wearable tech in the mix to provide a fresh level of health records. Mobile sensors were worn by the telemedicine cohort to monitor patient’s activities, both deliberate and unintentional, during the day.

Throughout telemedicine sessions, the submitted information is analyzed to determine busy periods when individuals had Parkinson’s signs.

“We recruited Parkinson’s patients with either tremors or involuntary movements,” says Joshua Yoneda, SMP student and co-author of the study. “We then divided them into two groups—some using telehealth and device-based health tracking and others attending traditional face-to-face appointments.”

Generally, individuals who used wearable technology in conjunction with telemedicine visits to get specialized treatment had excellent interactions & medical results.

“With the integration of accurate and reliable data from wearable devices, we were able to tailor a patient’s medication to better manage their symptoms throughout the day,” adds Wile.

Participants are administered a set of items from the standardized Parkinson Disease Quality of Life Index as part of the research. All research subgroups are evaluated at six-week, three-month, and six-month intervals.

“There’s definitely a strong case to leverage multiple technologies to improve a patient’s quality of life and limit the added stress and cost associated with travel,” says Yoneda.

Notwithstanding the obstacles, continuing advancements in sensor technical complexity, adaptability, and fashionability have provided possibilities to capture disease-relevant information utilizing patient-relevant targeting responsive to PD-specific signs and milestones.

Technology was needed to turn these potentials into good care, healthier body alternatives for PD sufferers, and ultimately improved healthcare treatment results.

They need to be 1) designed as new systems that can be linked with electronic health records, 2) suited for data collection of movement and non-motor events, and 3) incorporated into therapy delivery methods.

The goal of the Task Force on Technology of the World Parkinson and Motion Disorder Society is to change the present practice of merely adopting technological tools to fulfill pain care and research endpoints.

As a result, the Task Force will work to improve the scientific and administrative environments for developing technologies by persuading the FDA and EMA, for example, to sanction open platform frameworks for technology-based measures and therapies.